Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Control of the timing and dosage of IGF-I delivery from encapsulated cells.

Patel RS, Chang A, Lysaght MJ, Morgan JR.

J Tissue Eng Regen Med. 2013 Jun;7(6):470-8. doi: 10.1002/term.546. Epub 2012 Feb 9.

PMID:
22319007
2.

How to teach artificial organs.

Zapanta CM, Borovetz HS, Lysaght MJ, Manning KB.

ASAIO J. 2011 Sep-Oct;57(5):466-9. doi: 10.1097/MAT.0b013e31823005f0.

PMID:
21869622
3.

A localizable, biological-based system for the delivery of bioactive IGF-1 utilizing microencapsulated genetically modified human fibroblasts.

Patel RS, Temu TM, Jeanbart L, Morgan JR, Lysaght MJ.

ASAIO J. 2009 May-Jun;55(3):259-65. doi: 10.1097/MAT.0b013e31819b0365.

PMID:
19390433
4.

Origins.

Lysaght MJ, Crager J.

Tissue Eng Part A. 2009 Jul;15(7):1449-50. doi: 10.1089/ten.tea.2007.0412. No abstract available.

PMID:
19327019
5.

Wearable artificial kidneys...2008. What's new?

Shaldon S, Lysaght MJ.

Nephrol Dial Transplant. 2008 Sep;23(9):2716-7; discussion 2718-9. doi: 10.1093/ndt/gfn408. No abstract available.

PMID:
18710830
6.

Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics.

Lysaght MJ, Jaklenec A, Deweerd E.

Tissue Eng Part A. 2008 Feb;14(2):305-15. doi: 10.1089/tea.2007.0267.

PMID:
18333783
7.

Microencapsulated cells genetically modified to overexpress human transforming growth factor-beta1: viability and functionality in allogeneic and xenogeneic implant models.

Paek HJ, Campaner AB, Kim JL, Golden L, Aaron RK, Ciombor DM, Morgan JR, Lysaght MJ.

Tissue Eng. 2006 Jul;12(7):1733-9.

PMID:
16889504
8.

Origin of insulin secreted from islet-like cell clusters derived from murine embryonic stem cells.

Paek HJ, Moise LJ, Morgan JR, Lysaght MJ.

Cloning Stem Cells. 2005;7(4):226-31.

PMID:
16390258
9.

In vitro characterization of TGF-beta1 release from genetically modified fibroblasts in Ca(2+)-alginate microcapsules.

Paek HJ, Campaner AB, Kim JL, Aaron RK, Ciombor DM, Morgan JR, Lysaght MJ.

ASAIO J. 2005 Jul-Aug;51(4):379-84.

PMID:
16156303
10.

Sequestration and synthesis: the source of insulin in cell clusters differentiated from murine embryonic stem cells.

Paek HJ, Morgan JR, Lysaght MJ.

Stem Cells. 2005 Aug;23(7):862-7. Epub 2005 May 11.

11.

California's Proposition 71.

Lysaght MJ.

Tissue Eng. 2005 Mar-Apr;11(3-4):xi-xiii. No abstract available.

PMID:
15869414
12.

Oral administration of biochemically active microcapsules to treat uremia: new insights into an old approach.

O'Loughlin JA, Bruder JM, Lysaght MJ.

J Biomater Sci Polym Ed. 2004;15(11):1447-61.

PMID:
15648574
13.

In vivo and in vitro degradation of urea and uric acid by encapsulated genetically modified microorganisms.

O'Loughlin JA, Bruder JM, Lysaght MJ.

Tissue Eng. 2004 Sep-Oct;10(9-10):1446-55.

PMID:
15588404
14.

Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes.

O'Loughlin JA, Bruder JM, Lysaght MJ.

ASAIO J. 2004 May-Jun;50(3):253-60.

PMID:
15171478
15.

Tissue engineering: the end of the beginning.

Lysaght MJ, Hazlehurst AL.

Tissue Eng. 2004 Jan-Feb;10(1-2):309-20.

PMID:
15009955
16.

Private sector development of stem cell technology and therapeutic cloning.

Lysaght MJ, Hazlehurst AL.

Tissue Eng. 2003 Jun;9(3):555-61.

PMID:
12857423
17.

Immunosuppression, immunoisolation and cell therapy.

Lysaght MJ.

Mol Ther. 2003 Apr;7(4):432. No abstract available.

18.

Kinetics and dosing predictions for daily haemofiltration.

Leypoldt JK, Jaber BL, Lysaght MJ, McCarthy JT, Moran J.

Nephrol Dial Transplant. 2003 Apr;18(4):769-76.

PMID:
12637647
19.
20.

The growth of tissue engineering.

Lysaght MJ, Reyes J.

Tissue Eng. 2001 Oct;7(5):485-93. Review.

PMID:
11694183

Supplemental Content

Loading ...
Support Center